Bionetide
Phase 3Peptide
Bionetide is one of 9 small molecule programs targeting Rett syndrome. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
8 competitors in Rett Syndrome
#DrugCompanyPhaseTrials
1Epidiolex
Jazz PharmaceuticalsApproved
Risperdal
WWim Janssens
Approved
Norpramin
VValidus Pharmaceuticals
Approved
Remeron
OOrganon and Co
Phase 2
Bionetide
BBiomed Industries, Inc.
Phase 3
Fenfluramine Hydrochloride
NNYU Langone Health
Phase 3
Aricept
EisaiPreclinical
Esketamine Hydrochloride
TThe Second Hospital of Anhui Medical University
Phase 1
Topamax
WWim Janssens
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Bionetide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Peptide[2]
- Highest Phase
- Phase 3[1]
- Company
- BBiomed Industries, Inc.